AB0541 EFFICACY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PRIMARY SJÖGREN'S SYNDROME-RELATED INTER...
AB0541 EFFICACY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PRIMARY SJÖGREN'S SYNDROME-RELATED INTERSTITIAL LUNG DISEASE
About this item
Full title
Author / Creator
Erbasan, F. , Öğüt, T.S. , Dibil, M. , Nokay, M. , Terzioğlu, M.E. and Yazisiz, V.
Publisher
Kidlington: Elsevier B.V
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier B.V
Subjects
More information
Scope and Contents
Contents
Primary Sjögren's syndrome (pSS) is mainly characterized by dry mouth and eyes due to loss of secretory function of exocrine glands, and systemic involvement can be seen [1]. One of the most important causes of morbidity and mortality in pSS is interstitial lung disease (ILD) [2]. Primary SS-related ILD (pSS-ILD) treatment is usually based on the c...
Alternative Titles
Full title
AB0541 EFFICACY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PRIMARY SJÖGREN'S SYNDROME-RELATED INTERSTITIAL LUNG DISEASE
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2855720183
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2855720183
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.6277
